PL2334672T3 - Związki 4,5,6,7-tetrahydroimidazo[4,5-C]pirydynowe jako inhibitory SSAO - Google Patents
Związki 4,5,6,7-tetrahydroimidazo[4,5-C]pirydynowe jako inhibitory SSAOInfo
- Publication number
- PL2334672T3 PL2334672T3 PL09783085T PL09783085T PL2334672T3 PL 2334672 T3 PL2334672 T3 PL 2334672T3 PL 09783085 T PL09783085 T PL 09783085T PL 09783085 T PL09783085 T PL 09783085T PL 2334672 T3 PL2334672 T3 PL 2334672T3
- Authority
- PL
- Poland
- Prior art keywords
- ssao
- tetrahydroimidazo
- inhibitors
- pyridine compounds
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0801979 | 2008-09-16 | ||
US10673408P | 2008-10-20 | 2008-10-20 | |
EP09783085.5A EP2334672B1 (en) | 2008-09-16 | 2009-09-16 | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO |
PCT/EP2009/062011 WO2010031789A1 (en) | 2008-09-16 | 2009-09-16 | New compounds i |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2334672T3 true PL2334672T3 (pl) | 2014-03-31 |
Family
ID=41226693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09783085T PL2334672T3 (pl) | 2008-09-16 | 2009-09-16 | Związki 4,5,6,7-tetrahydroimidazo[4,5-C]pirydynowe jako inhibitory SSAO |
Country Status (16)
Country | Link |
---|---|
US (7) | US8263616B2 (pl) |
EP (1) | EP2334672B1 (pl) |
JP (1) | JP5539989B2 (pl) |
CN (1) | CN102232073B (pl) |
AU (1) | AU2009294660B2 (pl) |
BR (1) | BRPI0918602B8 (pl) |
CA (1) | CA2737527C (pl) |
DK (1) | DK2334672T3 (pl) |
EA (1) | EA019167B1 (pl) |
ES (1) | ES2440279T3 (pl) |
HK (1) | HK1159102A1 (pl) |
MX (1) | MX2011002581A (pl) |
NZ (1) | NZ592238A (pl) |
PL (1) | PL2334672T3 (pl) |
PT (1) | PT2334672E (pl) |
WO (1) | WO2010031789A1 (pl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA019167B1 (ru) | 2008-09-16 | 2014-01-30 | Проксимаген Лимитед | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы |
UA112154C2 (uk) * | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
CN102311396B (zh) * | 2010-07-05 | 2015-01-07 | 暨南大学 | 一种吡嗪类衍生物和其制备方法及在制药中的应用 |
FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
SG11201400277VA (en) | 2011-09-14 | 2014-05-29 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201304526D0 (en) * | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
AU2014279863A1 (en) | 2013-06-12 | 2016-01-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
GB201416446D0 (en) * | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
KR102137350B1 (ko) | 2015-03-02 | 2020-07-23 | 닛본 덴끼 가부시끼가이샤 | 디코딩 장치, 수신기기, 송신기기, 송수신 시스템, 디코딩 방법, 및 디코딩 프로그램이 저장된 저장매체 |
GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
GB201507048D0 (en) | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Treatment of pain |
GB201507036D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | Crystalline enzyme inhibitor compound |
GB201513115D0 (en) | 2015-07-24 | 2015-09-09 | Proximagen Ltd | New therapeutic compound and use in therapy |
CA3005353A1 (en) | 2015-11-20 | 2017-05-26 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
JP2019502672A (ja) * | 2015-12-07 | 2019-01-31 | ベネボレンタイ ケンブリッジ リミティド | 疼痛の治療のためのvap−1阻害剤 |
GB201618029D0 (en) | 2016-10-25 | 2016-12-07 | Proximagen Ltd | New process |
EP3902802A4 (en) * | 2018-12-28 | 2022-09-07 | Forma Therapeutics, Inc. | COMPOSITIONS FOR INHIBITING UBIQUITIN-SPECIFIC PROTEASE 1 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141899A (en) * | 1976-01-07 | 1979-02-27 | Societa' Farmaceutici Italia S.P.A. | 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives |
JPS5285191A (en) * | 1976-01-07 | 1977-07-15 | Farmaceutici Italia | Novel 4*5*6*77tetrahydroimidazoo *4*55c*pyridine derivative process for preparing same and medicine having antiiulcer antiisecretion and antiicolline activities containing same |
IT1098015B (it) * | 1978-08-07 | 1985-08-31 | Farmaceutici Italia | Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati |
US6908926B1 (en) | 1999-04-16 | 2005-06-21 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
SE0004101D0 (sv) * | 2000-11-09 | 2000-11-09 | Pharmacia Ab | New use |
US6576249B1 (en) * | 2000-11-13 | 2003-06-10 | El Gendler | Bone putty and method |
EA019167B1 (ru) | 2008-09-16 | 2014-01-30 | Проксимаген Лимитед | Соединения, ингибирующие активность семикарбазид-чувствительной аминооксидазы |
-
2009
- 2009-09-16 EA EA201100391A patent/EA019167B1/ru not_active IP Right Cessation
- 2009-09-16 AU AU2009294660A patent/AU2009294660B2/en not_active Ceased
- 2009-09-16 NZ NZ592238A patent/NZ592238A/xx not_active IP Right Cessation
- 2009-09-16 EP EP09783085.5A patent/EP2334672B1/en active Active
- 2009-09-16 PL PL09783085T patent/PL2334672T3/pl unknown
- 2009-09-16 US US13/062,318 patent/US8263616B2/en not_active Expired - Fee Related
- 2009-09-16 WO PCT/EP2009/062011 patent/WO2010031789A1/en active Application Filing
- 2009-09-16 DK DK09783085.5T patent/DK2334672T3/da active
- 2009-09-16 CA CA2737527A patent/CA2737527C/en not_active Expired - Fee Related
- 2009-09-16 JP JP2011526516A patent/JP5539989B2/ja active Active
- 2009-09-16 BR BRPI0918602A patent/BRPI0918602B8/pt not_active IP Right Cessation
- 2009-09-16 CN CN200980136970.1A patent/CN102232073B/zh not_active Expired - Fee Related
- 2009-09-16 PT PT97830855T patent/PT2334672E/pt unknown
- 2009-09-16 MX MX2011002581A patent/MX2011002581A/es active IP Right Grant
- 2009-09-16 ES ES09783085.5T patent/ES2440279T3/es active Active
-
2011
- 2011-12-16 HK HK11113628.0A patent/HK1159102A1/xx not_active IP Right Cessation
-
2012
- 2012-08-06 US US13/567,146 patent/US8569338B2/en active Active
-
2013
- 2013-10-25 US US14/062,969 patent/US9035066B2/en active Active
-
2015
- 2015-04-13 US US14/684,813 patent/US9493457B2/en active Active
-
2016
- 2016-10-27 US US15/335,751 patent/US9890160B2/en active Active
-
2017
- 2017-12-29 US US15/858,407 patent/US10399973B2/en active Active
-
2019
- 2019-07-17 US US16/514,413 patent/US11040969B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2334672T3 (pl) | Związki 4,5,6,7-tetrahydroimidazo[4,5-C]pirydynowe jako inhibitory SSAO | |
HRP20170255T1 (hr) | Postupak za pripremu spojeva korisnih kao inhibitori sglt-a | |
IL238338A0 (en) | Processes for preparing sglt2 inhibitors | |
AP2806A (en) | 3H-imidazo[4,5-C] pyridine-6-carboxamides as anti-infammatory agents | |
IL211148A0 (en) | 3h-imidazo [4,5-c] pyridine-6-carboxamides as anti-inflammatory agents | |
ZA201304646B (en) | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace) | |
IL229993A0 (en) | A process for the preparation of 8-Alkoxy[1,2,4]triazolo[5,1-c]pyrimidine-2 amines 5-converted | |
HRP20130641T1 (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
SI2321312T1 (sl) | Postopek za pripravo paliperidona |